146 related articles for article (PubMed ID: 12633529)
1. The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.
Garside R; Round A; Dalziel K; Stein K; Royle P
Health Technol Assess; 2002; 6(33):1-162. PubMed ID: 12633529
[No Abstract] [Full Text] [Related]
2. Position paper on imatinib mesylate in chronic myeloid leukaemia.
O'Brien SG; Rule SA
Br J Haematol; 2002 Oct; 119(1):268-72. PubMed ID: 12358935
[No Abstract] [Full Text] [Related]
3. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia.
Dalziel K; Round A; Garside R; Stein K
Pharmacoeconomics; 2005; 23(5):515-26. PubMed ID: 15896102
[TBL] [Abstract][Full Text] [Related]
4. Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
Goldman J
Nat Clin Pract Oncol; 2005 Mar; 2(3):126-7. PubMed ID: 16264901
[No Abstract] [Full Text] [Related]
5. Imatinib for chronic myeloid leukaemia: a NICE mess.
Rajaratnam G; Edwards J
Lancet; 2001 Dec; 358(9296):1902. PubMed ID: 11741655
[No Abstract] [Full Text] [Related]
6. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
Dalziel K; Round A; Stein K; Garside R; Price A
Health Technol Assess; 2004 Jul; 8(28):iii, 1-120. PubMed ID: 15245690
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate--a new oral targeted therapy.
Savage DG; Antman KH
N Engl J Med; 2002 Feb; 346(9):683-93. PubMed ID: 11870247
[No Abstract] [Full Text] [Related]
8. NICE backs leukaemia drug after manufacturer drops price.
Wise J
BMJ; 2012 Mar; 344():e2274. PubMed ID: 22442356
[No Abstract] [Full Text] [Related]
9. Imatinib for chronic myeloid leukaemia: a NICE mess.
O'Brien SG
Lancet; 2001 Dec; 358(9296):1902-3. PubMed ID: 11741654
[No Abstract] [Full Text] [Related]
10. Imatinib for chronic myeloid leukaemia: a NICE mess.
Barbour V
Lancet; 2001 Nov; 358(9292):1478. PubMed ID: 11705557
[No Abstract] [Full Text] [Related]
11. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
Warren E; Ward S; Gordois A; Scuffham P
Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
[TBL] [Abstract][Full Text] [Related]
12. [Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ].
Groot MT; Ossenkoppele GJ; Kramer MH; van den Boom G; Huijgens PC; Uyl-de Groot CA
Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1460-5. PubMed ID: 12908349
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
Loveman E; Cooper K; Bryant J; Colquitt JL; Frampton GK; Clegg A
Health Technol Assess; 2012; 16(23):iii-xiii, 1-137. PubMed ID: 22564553
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
[No Abstract] [Full Text] [Related]
15. Chronic myelogenous leukemia.
Klemm J; Mehr SR
Am J Manag Care; 2012 May; 18(3 Spec No.):SP105-7. PubMed ID: 22642273
[No Abstract] [Full Text] [Related]
16. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
Taylor MJ; Scuffham PA
Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798
[TBL] [Abstract][Full Text] [Related]
19. Targeted cancer therapy: from bench to bedside to patient.
Gellad WF
J Clin Oncol; 2014 Feb; 32(4):268-70. PubMed ID: 24366939
[No Abstract] [Full Text] [Related]
20. Chronic myelogenous leukaemia market.
Storey S
Nat Rev Drug Discov; 2009 Jun; 8(6):447. PubMed ID: 19483705
[No Abstract] [Full Text] [Related]
[Next] [New Search]